Moderna says its COVID-19 vaccine is safe for children as young as six months after the completion of a clinical trial.
Moderna, the American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, has taken to social media to announce that it has completed Phase 2 and 3 clinical trials for its vaccine in children as young as six months old.
The company is hoping to have the shot ready for the vaccinating of children under the age of 5 within a matter of months. The Phase 2 and 3 trials were recently completed and included the six months to two years old age group, and the two to six years old groups.
We're announcing positive interim data from the Phase 2/3 KidCOVE study of our #COVID19 vaccine (mRNA-1273) in children 6 months to under 2 years and 2 years to under 6 years of age.https://t.co/CqdRMSv3Kv pic.twitter.com/whcObVY4CD
— Moderna (@moderna_tx) March 23, 2022
However, not all experts agree that the vaccine is needed for children as they face comparatively little risk from the virus.
